Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of therapeutic BCG for prevention of recurrence after surgery in adults with non-muscle-invasive bladder cancer
CTR20244824Phase 3Active
- Sponsor
- Anhui Zhifei Longcom Biopharmaceutical
- Start
- Apr 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of bcg vaccine in non-muscle-invasive bladder cancer (NMIBC), transitional cell carcinoma of the bladder (TCC), Bladder cancer in situ (CIS), sponsored by Anhui Zhifei Longcom Biopharmaceutical. Started Apr 2025; status: active.
02
Drugs
bcg vaccine
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)transitional cell carcinoma of the bladder (TCC)Bladder cancer in situ (CIS)
Beyond the preview
Go deeper on CTR20244824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244824.